Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Leukemia, Myeloid, Acute 146Leukemia 49Precursor Cell Lymphoblastic Leukemia-Lymphoma 46Congenital Abnormalities 30Myelodysplastic Syndromes 25Leukemia, Monocytic, Acute 23Recurrence 22Leukemia, Myelomonocytic, Acute 22Leukemia, Erythroblastic, Acute 20Leukemia, Megakaryoblastic, Acute 19Lymphoma 17Leukemia, Biphenotypic, Acute 13Lymphoma, Non-Hodgkin 12Burkitt Lymphoma 12Lymphoma, Large B-Cell, Diffuse 11Leukemia, Myelomonocytic, Chronic 11Blast Crisis 11Lymphoma, Mantle-Cell 9Leukemia, Lymphocytic, Chronic, B-Cell 9Lymphoma, Follicular 8Lymphoma, Large-Cell, Immunoblastic 7Leukemia, Eosinophilic, Acute 7Leukemia, Basophilic, Acute 7Myeloproliferative Disorders 6Lymphoma, B-Cell, Marginal Zone 6Hodgkin Disease 6Hematologic Neoplasms 6Myelodysplastic-Myeloproliferative Diseases 5Leukemia, Promyelocytic, Acute 5Leukemia, Myeloid, Accelerated Phase 5

Interventions

Temozolomide 38Radiotherapy 22Radiosurgery 22Radiation 11Magnetic Resonance Spectroscopy 11Irinotecan 11Cyclophosphamide 11Etoposide 10Surgical Procedures, Operative 9Erlotinib Hydrochloride 9Carmustine 9pembrolizumab 8Filgrastim 8Carboplatin 8Bevacizumab 7Vincristine 6Sorafenib 6O(6)-benzylguanine 6Nivolumab 6Flucytosine 6Aminolevulinic Acid 6temsirolimus 5sargramostim 5Vorinostat 5Trastuzumab 5Topotecan 5Lomustine 5Imatinib Mesylate 5Granulocyte Colony-Stimulating Factor 5Everolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Brain Neoplasms × Cytarabine × Clear all
NCT03654716 2025-02-14

Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

Dana-Farber Cancer Institute

Phase 1 Completed
21 enrolled
CNSLymphoidOther hematologic neoplasm

Brain Neoplasms, Leukemia, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡